- Home
- MFIN vs GLSI Comparison
MFIN vs GLSI Comparison
Compare MFIN & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MFIN
- GLSI
- Stock Information
- Founded
- MFIN 1995
- GLSI 2006
- Country
- MFIN United States
- GLSI United States
- Employees
- MFIN N/A
- GLSI N/A
- Industry
- MFIN Finance: Consumer Services
- GLSI Biotechnology: Pharmaceutical Preparations
- Sector
- MFIN Finance
- GLSI Health Care
- Exchange
- MFIN Nasdaq
- GLSI Nasdaq
- Market Cap
- MFIN 190.0M
- GLSI 197.1M
- IPO Year
- MFIN 1996
- GLSI 2020
- Fundamental
- Price
- MFIN $9.56
- GLSI $13.55
- Analyst Decision
- MFIN
- GLSI Strong Buy
- Analyst Count
- MFIN 0
- GLSI 1
- Target Price
- MFIN N/A
- GLSI $38.00
- AVG Volume (30 Days)
- MFIN 62.7K
- GLSI 30.1K
- Earning Date
- MFIN 10-29-2024
- GLSI 11-14-2024
- Dividend Yield
- MFIN 4.60%
- GLSI N/A
- EPS Growth
- MFIN N/A
- GLSI N/A
- EPS
- MFIN 1.69
- GLSI N/A
- Revenue
- MFIN $293,257,000.00
- GLSI N/A
- Revenue This Year
- MFIN N/A
- GLSI N/A
- Revenue Next Year
- MFIN $10.95
- GLSI N/A
- P/E Ratio
- MFIN $5.65
- GLSI N/A
- Revenue Growth
- MFIN 18.48
- GLSI N/A
- 52 Week Low
- MFIN $6.48
- GLSI $8.00
- 52 Week High
- MFIN $10.19
- GLSI $21.44
- Technical
- Relative Strength Index (RSI)
- MFIN 56.93
- GLSI 50.73
- Support Level
- MFIN $9.35
- GLSI $12.51
- Resistance Level
- MFIN $9.70
- GLSI $14.31
- Average True Range (ATR)
- MFIN 0.25
- GLSI 1.02
- MACD
- MFIN -0.07
- GLSI -0.03
- Stochastic Oscillator
- MFIN 28.41
- GLSI 59.71
About MFIN Medallion Financial Corp.
Medallion Financial Corp is a finance company that originates and services loans in various industries. Its operating segments include recreation, home improvement, commercial lending, medallion lending and Corporate and Other Investments. The company generates maximum revenue from the Recreation segment.
About GLSI Greenwich LifeSciences Inc.
Greenwich LifeSciences Inc is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. Its Product Candidates include; GP2, a HER2/neu transmembrane peptide that elicits a targeted immune response against HER2/neu-expressing cancers, GM-CSF Immunoadjuvant has been shown to enhance monocyte and neutrophil cytotoxicity against melanoma tumor cells and to enhance activity-dependent cellular cytotoxicity of monocytes and neutrophils against targets coated with the anti-ganglioside antibodies, and Cancer immunotherapy seeks to stimulate an individual's immune system to selectively attack cancer cells to inhibit the spread of cancer.